Effects of topiramate on oral dyskinesia induced by reserpine

Effects of topiramate on oral dyskinesia induced by reserpine

Autor Araujo, N. P. Google Scholar
Abilio, V. C. Google Scholar
Silva, R. H. Google Scholar
Pereira, R. C. Google Scholar
Carvalho, R. C. Google Scholar
Gonzalez, C. Google Scholar
Bellot, R. G. Google Scholar
Castro, JPMV Google Scholar
Fukushiro, D. F. Google Scholar
Rodrigues, MSD Google Scholar
Chinen, C. C. Google Scholar
Frussa, R. Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Recently, we have described the antidyskinetic property of the GABA mimetic drug valproic acid on reserpine-induced oral dyskinesia, an animal model that has been related to tardive as well as acute dyskinesias, which are associated with important neuropathologies. the present study investigates the effects of different doses of the GABA mimetic anticonvulsant topiramate on the manifestation of reserpine-induced orofacial dyskinesia. Female EPM-M1 mice received two injections of control solution or of 0.5 mg/kg reserpine separated by 48 h. Twenty-four hours after the second reserpine or control solution injection, animals were acutely treated with control solution or topiramate (1, 3, 10 or 30 mg/kg) and were observed for quantification of oral dyskinesia or general activity in an open-field. in order to verify the effects of topiramate per se on oral dyskinesia or general activity, female EPM-M1 mice were acutely treated with control solution or 1, 3, 10 or 30 mg/kg topiramate and observed for quantification of oral dyskinesia and general activity. the highest dose of topiramate completely abolished the manifestation of reserpine-induced oral dyskinesia whereas the doses of 3 and 10 mg/kg significantly attenuated it. None of the doses of the anticonvulsant modified spontaneous locomotion frequency or oral movements, whereas spontaneous rearing frequency was decreased by 3, 10 and 30 mg/kg topiramate. the highest dose of topiramate did not modify general activity in reserpine-treated mice. These results support the potential therapeutic use of topiramate in the treatment of oral dyskinesias. (C) 2004 Elsevier Inc. All rights reserved.
Assunto anticonvulsant
movement disorders
Idioma Inglês
Data 2004-12-15
Publicado em Brain Research Bulletin. Oxford: Pergamon-Elsevier B.V., v. 64, n. 4, p. 331-337, 2004.
ISSN 0361-9230 (Sherpa/Romeo, fator de impacto)
Editor Elsevier B.V.
Extensão 331-337
Fonte http://dx.doi.org/10.1016/j.brainresbull.2004.09.001
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000225601200007
URI http://repositorio.unifesp.br/handle/11600/28051

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)